Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.
- 50% revenue share from Yale on deoxymab IP
- IP assigned to university-backed start-up for development
- Patrys reduces capital outlay but retains upside exposure
- Ongoing clinical research collaborations continue
- Funds from recent placement support development milestones
Strategic Revenue Sharing Deal with Yale University
Patrys Limited (ASX:PAB) has struck a significant commercialisation deal with Yale University, assigning its deoxymab intellectual property portfolio to the university in exchange for 50% of all future commercialisation revenue. This revenue includes licensing fees, royalties, milestone payments, equity stakes, and other forms of consideration tied directly to the deoxymab IP.
The deal marks a strategic pivot by Patrys to reduce its future capital requirements for developing the deoxymab platform while preserving meaningful long-term shareholder exposure to any upside. Under the agreement, Yale will take on the bulk of research and development costs, either directly or through third-party funding, allowing Patrys to conserve cash and internal resources.
University-Backed Start-Up to Drive Next Development Phase
Following the IP assignment, Yale plans to transfer the deoxymab portfolio into a new university-supported start-up entity, with Patrys becoming a direct shareholder. This structure aims to leverage academic research capabilities and specialist external funding pathways to advance the platform more efficiently.
Patrys will maintain an active role through ongoing clinical research collaborations, including pre-clinical vasculitis studies with Monash University. These efforts are designed to strengthen the scientific foundation and commercial attractiveness of deoxymab as it progresses towards potential therapeutic applications.
Capital Deployment and Development Focus
The company intends to allocate funds raised from its recent A$3.2 million placement towards advancing key milestones across its pipeline, including the deoxymab portfolio and its injectable quetiapine program, RLS-2202. Approximately A$683,000 is earmarked for intellectual property maintenance and preclinical research related to deoxymab, while nearly A$2 million supports RLS-2202 clinical development efforts.
This funding strategy aligns with Patrys’ broader approach to balancing internal development with external partnerships to manage capital efficiently while pushing multiple programs forward. The injectable quetiapine program is advancing towards Phase 1A trials, supported by recent CRO appointments and manufacturing milestones.
Balancing Risk and Opportunity in Deoxymab’s Future
While the revenue sharing deal secures Patrys a substantial stake in any future commercial returns from deoxymab, the timing and scale of such returns remain uncertain. The university-backed start-up is yet to be established, and commercialisation depends on ongoing development, funding, and regulatory approvals.
Nonetheless, this transaction reflects a pragmatic approach to de-risking the development pathway by leveraging Yale’s academic and commercialisation infrastructure. It also preserves Patrys’ strategic interest in a platform its founder, Dr James Hansen, believes could transform treatment paradigms across multiple diseases.
Bottom Line?
Patrys’ deal with Yale rebalances risk and capital needs while keeping a foot in the door of deoxymab’s commercial future.
Questions in the middle?
- How quickly will the university-backed start-up entity be established and operational?
- What external funding sources will Yale leverage to advance the deoxymab portfolio?
- How will Patrys balance resources between deoxymab and its injectable quetiapine program?